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Available online 9 May 2019Background: Missensemutations in keratin 5 and 14 genes cause the severe skin fragility disorder epidermolysis
bullosa simplex (EBS) by collapsing of the keratin cytoskeleton into cytoplasmic protein aggregates. Despite in-
tense efforts, no molecular therapies are available, mostly due to the complex phenotype of EBS, comprising cell
fragility, diminished adhesion, skin inﬂammation and itch.
Methods: We extensively characterized KRT5 and KRT14mutant keratinocytes from patients with severe gener-
alized EBS following exposure to the chemical chaperone 4-phenylbutyrate (4-PBA).
Findings: 4-PBA diminished keratin aggregates within EBS cells and ameliorated their inﬂammatory phenotype.
Chemoproteomics of 4-PBA-treated and untreated EBS cells revealed reduced IL1β expression- but also showed
activation of Wnt/β-catenin and NF-kB pathways. The abundance of extracellular matrix and cytoskeletal pro-
teins was signiﬁcantly altered, coinciding with diminished keratinocyte adhesion and migration in a 4-PBA
dose-dependent manner.
Interpretation: Together, our study reveals a complex interplay of beneﬁts and disadvantages that challenge the
use of 4-PBA in skin fragility disorders.







Epidermolysis bullosa simplex (EBS) is characterized by skin fragility
manifesting with blisters and erosions caused by minor mechanical
trauma. At the ultrastructural level, EBS is characterized by
intraepidermal tissue separation. The phenotype ranges from relatively




an keratinocytes, treated with
logy, Medical Faculty, Medical
burg, Germany.
D. Kiritsi).
. This is an open access article underThe repeated palmoplantar blistering leads to progressive hyperkerato-
sis of the palms and soles, which begins in childhood and is the major
concern for affected adult individuals. Mucosal involvement in severe
generalized EBS (EBS sev gen) may interfere with feeding, especially
in neonates and infants [1]. The disease is primarily caused by domi-
nantly inherited mutations in the keratin 5 (KRT5) or 14 genes
(KRT14). KRT5 and KRT14 form extremely stable dimer and tetramer
subunits. The resulting intermediate ﬁlaments organize themselves
into cross-linked networks. Their structural support function is lost, if
one of the proteins is disturbed due to mutations [2].
In the past, heat stress-induced keratin aggregation has been
observed in primary keratinocytes derived from EBS patients [3].
However, primary keratinocytes possess a limited lifespan and hetero-
geneous behavior with increasing passage numbers, making them
unsuitable formore extensive functional assays. A large part of the path-
ophysiological work on EBS is based on animal models, which cannotthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
4-PBA has been suggested towork as an anti-aggregation agent in
genetic skin fragility disorders. Therefore, a therapeutic potential
has been assumed and indeed preliminary in vitro data have sug-
gested disease ameliorating benefit of 4-PBA on the cellular level.
Added value of this study
Here we conducted a detailed analysis of the therapeutic applica-
bility of 4-PBA not only assessing its anti-aggregating modalities
in the setting of epidermolysis bullosa simplex due to impaired
functionality of keratin filaments, but also its larger contextual ac-
tions and outcomes. 4-PBAwas tested over a range of concentra-
tions in multiple donor-derived materials and with different
analytical techniques, ranging from targeted to global analyses.
Implications of all the available evidence
Our study indicates low dose 4-PBAhas some favorable effects on
epidermolysis bullosa simplex keratinocytes, although it comes
with some potentially unfavorable side effects. Collectively,
weighing the advantages and disadvantages of 4-PBA in the set-
ting of epidermolysis bullosa simplex reveals that it cannot be con-
sidered a good therapeutic candidate. However, other less broad
spectrum molecular chaperones targeting aggregate formation
and ER stress could represent possible therapeutic tools. Their ef-
fects on cellular adhesion and migration must first be carefully
investigated.
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ferent from human skin [4]. In addition, there are signiﬁcant differences
between different mouse models and affected mice die soon after birth
[5–7]. We and others [8–12] have established patient-derived immor-
talized cell lines as a reproducible EBS model to characterize the role
of intermediate ﬁlament (IF) protein aggregates in EBS keratinocytes
and the cellular response of EBS keratinocytes to thermal and chemical
stress. As published reports imply differences between KRT5 and KRT14-
mutated cells [13], in the present study we investigated cells from pa-
tients with common missense KRT5 and KRT14mutations to better un-
derstand the molecular consequences and underlying disease
mechanisms.
4-phenylbutyrate (4-PBA) is an approved orphan drug, which is
used to treat urea cycle disorders, as its metabolites offer an alternative
pathway to allow for the excretion of excess nitrogen. 4-PBA has been
shown to facilitate protein folding, suppressing ER stress-mediated ap-
optosis by inhibiting eukaryotic initiation factor 2a (eIF2a) phosphory-
lation, CCAAT (highly conserved promoter region of the Grp genes)/
enhancer-binding protein homologous protein (CHOP) induction, and
caspase-12 activation [14,15]. The chemical chaperone 4-PBA has also
been shown to antagonize protein aggregation in several genetic and in-
ﬂammatory disorders, e.g. muscular dystrophies/ myopathies [16,17]
and Parkinson's disease [18]. Currently, 49 clinical trials are listed in
the ClinicalTrials.gov registry. Notably, small pilot studies have been
performed with keratinocytes of skin fragility patients. 4-PBA reduced
the formation of speciﬁcally heat-induced keratin aggregates in EBS
cells [3] and increased mRNA and protein levels of the mutant protein
kindlin-1 in cells of a Kindler syndrome patient [19]. It also improved
cell spreading and proliferation in a recombinant system [19]. In cells
of patients with epidermolytic ichthyosis due to KRT1 or KRT10muta-
tions, 4-PBA treatment reduced the fraction of aggregate-containing
cells, but also impaired mRNA expression of keratins 1 and 10 [20]. 4-
PBAwas determined to be effective in patients with progressive familialintrahepatic cholestasis [21], and trials are ongoing for spinal muscular
atrophy and thalassemia.
In the present study, we took an interdisciplinary approach using
molecular, cell-biochemical and proteomics methods, to characterize
the effects of 4-PBA on keratinocytes derived from patients with EBS.
4-PBA treatment diminished the presence of keratin aggregates within
EBS cells and ameliorated their inﬂammatory phenotype; however, it
negatively impacted keratinocyte adhesion and migration in a dose-
dependent manner. Together, our study reveals a complex interplay of
beneﬁts and disadvantages that challenge the use of 4-PBA in skin fra-
gility disorders.
2. Results
2.1. 4-PBA reduces keratin aggregation in EBS keratinocyte lines
We generated HPV16-E6E7 immortalized control keratinocytes
from three healthy human subjects and from ﬁve patients with severe
generalized EBS. Two patients were heterozygous carriers of the com-
mon KRT5mutation p.E477K, and three were heterozygous carriers of
the most common KRT14mutation p.R125C. The patients had different
ages (9 days to 52 years old), but all suffered fromwidespread blistering
with early development of palmoplantar keratoderma (Supplemental
Fig. 1).
Aﬁrst observation revealed that only EBS keratinocyte andnot control
cell lines, display low degrees of IF aggregates, visualized as keratin
clumping, even at resting state. Around 4% of KRT5-mutated (KRT5mut)
and 30% of KRT14-mutated (KRT14mut) cells contained aggregates, as
shown by the staining with a keratin 5 antibody (Fig. 1A and B upper
panel). To analyzewhether the chemical chaperone 4-PBA has the capac-
ity to reduce those aggregates, cells were treated for 24 h with 1 mM 4-
PBA or left untreated. 4-PBA treatment resulted in a signiﬁcant reduction
in the fraction of cells with keratin aggregates in both KRT5mut and
KRT14mut keratinocytes (Fig. 1B, lower panel). To analyze whether 4-
PBA exhibits a time- dependent mode of action, the cell lines were also
treated for 48hwith 1mM4-PBA. This, however, did not result in a signif-
icant further reduction compared to 24h treatment (Fig. 1B, lower panel).
2.2. 4-PBA reduces the vulnerability of keratin IF networks to thermal and
chemical stress
To investigate how 4-PBA affects the response of EBS keratinocyte
cell lines to chemical stress, we treated the cells for 2 h with 0.1 μg/ml
ocadaic acid (OA), a serine/threonine phosphatase inhibitor that in-
duces a dynamic disassembly of the keratin IF networks due to their
hyper-phosphorylation [22].
In analogy to experiments with murine plectin-deﬁcient
keratinocytes [23], the course of the dynamic disassembly of the keratin
IF networks was also detected in our human keratinocyte cell lines.
Upon OA treatment, the formerly well-spread keratin IF network of
the EBS keratinocyte cell lines formed thick bundles of ﬁlaments, that
collapsed towards the nucleus (Fig. 1C, yellow arrows). The impact of
OA treatment in EBS keratinocytes was considerably more pronounced
than in control cells: around 40% of the KRT5mut cells and 80% of
KRT14mut cells displayed different degrees of aggregate formation.
Critically, the addition of 1 mM 4-PBA for 24 h before the OA treatment
had a moderate stabilizing effect on the IF network, which was signiﬁ-
cant both in the KRT14- and KRT5-mutated keratinocytes (Fig. 1C).
Next, we analyzed the effects of thermal stress on the IF network of
keratinocytes. Cells were either subjected to a heat shock treatment for
30min at 43 °C or left untreated. Cellswere then stainedwith a keratin 5
antibody to detect keratin aggregates. After heat shock, both the
KRT5mut and KRT14mut cell lines showed signiﬁcant increase in the
percentage of cells with perinuclear keratin aggregates. Comparable to
their response to chemical stress, the KRT14mut keratinocytes (60% of
cells with keratin aggregates) were also more susceptible to thermal
Fig. 1. Keratin aggregates in EBS keratinocytes at resting state and after stress: rescue by 4-PBA. A Analysis of the subcellular localisation of plectin and keratin 5 as shown by
immunoﬂuorescence staining of control normal human keratinocytes (NHK), keratinocytes from patients with mutations in the keratin 14 gene (KRT14mut) and keratinocytes from
patients with mutations in the keratin 5 gene (KRT5mut) with anti-plectin [Alexa555 (Cy3; red)] and keratin 5 [Alexa488 (GFP; green)] antibodies. Yellow arrows depict cells with
aggregates of their keratin IF network. Scale bar: 50 μm. B The upper panel shows quantiﬁcation of the keratinocytes with aggregates. The NHKs show no aggregates at resting state,
whereas they are signiﬁcantly more in KRT14mut than KRT5mut cells (for NHK versus KRT14mut ***P: 0.0001, for NHK versus KRT5mut *P: 0.0211 and for KRT5mut versus KRT14mut
***P: 0.0004, all done with student's t-test). In the lower panel the percentage of cells before (NHK, KRT14mut, KRT5mut) and after use of 4-PBA (NHK+, KRT14mut+, KRT5mut+) is
shown. The data are presented as mean ± SEM. Intermediate ﬁlament (IF) aggregates are signiﬁcantly less in cells treated with 1 mM 4-PBA [KRT14mut (***P b .0001, student's t-test)
and KRT5mut + cells (***P b .0001, student's t-test)], irrespective of the treatment time (24 or 48 h). C Immunoﬂuorescence staining for keratin 5 of EBS cells upon ocadaic treatment
(OA) and upon heat-shock (HS). In the 4 subimages, different KRT5mut and KRT14mut cells are shown, highlighting the different appearances of the cells. Thewell-spread keratin IF net-
work, as seen in NHK in A, forms thick bundles of ﬁlaments in several EBS keratinocytes, which seem to collapse towards the nucleus (yellow arrows). On the left quantiﬁcation graph, the
percentage of keratinocytes with aggregates before (NHK OA, KRT14mut OA, KRT5mut OA) and after use of 4-PBA (NHK OA+, KRT14mut OA+, KRT5mut OA+) are shown. The exper-
imentswere done in triplicates; the average of the three experiments is shown. Theuse of 4-PBA signiﬁcantly reduces the number of cellswith aggregates afterOA treatment [NHK-treated
cells (NHK OA+), KRT14mutated-treated cells (KRT14mut +) and KRT5mutated-treated cells (KRT5mut+): for all ***P b .0001, student's t-test]. EBS keratinocytes treated with HS
(KRT14mut HS and KRT5mut HS) showed signiﬁcant induction of aggregate formation [for both KRT14mut vs KRT14mut HS and KRT5mut vs KRT5mut HS ***P b .0001, student's t-
test], which was reversed after 4-PBA use [KRT14mut HS+ and KRT5mut HS+ ***P b .0001, student's t-test]. Scale bar: 50 μm.
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PBA treatment signiﬁcantly reduced keratin aggregation after heat
shock (Fig. 1C).
Our data suggest that the presence of IF aggregates in EBS
keratinocytes is mutation-dependent and more pronounced in
KRT14mut cells. In combination with chemical or thermal stress, muta-
tions in both genes trigger extensive keratin aggregation, that could be
partially prevented by treatment of the keratinocytes with 1 mM 4-PBA
for 24 h, whereas longer treatment did not further enhance the positive
effects.
2.3. 4-PBA negatively impacts cell adhesion, migration and formation of
cell-cell contacts
EBS is a skin fragility disorder accompanied by weakened epithelial
sheet integrity. Thus, we next assessed the effects of the 4-PBAtreatment on keratinocyte adhesion with use of two different assays,
to evaluate cell-cell and cell-extracellular matrix (ECM) adhesion. In
the dispase-based dissociation assay, cells were treated with dispase
for 30 min and then subjected to inversion. EBS keratinocytes dissoci-
ated easier than the control cells (Fig. 2A). We next investigated the ef-
fect of 4-PBA treatment on keratinocyte adhesion structures. After
1 mM4-PBA administration, we observed diminished cell-cell contacts,
as visualized by desmoplakin, plakoglobin (Fig. 2B) and E-cadherin
staining (Fig. 6A). Although this was not always statistically signiﬁcant,
we also observed reduced total amounts of these proteins as revealed by
immunoblotting (Fig. 2C, signiﬁcance shown in the ﬁgure legend). Be-
sides lower abundance, both plakoglobin and desmoplakin did not lo-
calize to cell-cell junctions, as is seen in untreated cells (Fig. 2B, white
arrows). Upon 4-PBA treatment no signiﬁcant differences in the abun-
dance of KRT14 and its binding partners KRT17 and KRT16 were ob-
served. KRT6 was enhanced after 4-PBA treatment, possibly as a
505M. Spörrer et al. / EBioMedicine 44 (2019) 502–515compensatorymechanism to the reduced adhesion [24] or alternatively
due to increased proliferation (Supplemental Figs 2 and Fig. 6B).
Cell-ECM adhesion was evaluated with two different assays. First,
we evaluated the effect of 4-PBA treatment on keratinocyte adhesion
on uncoated tissue culture plastic. This adhesion was normalized to ad-
hesion on collagen I (Col1) coating, representing F-actin and keratin
based ECM adhesion [25], for each cell type. The EBS keratinocytes ad-
hered with higher force than the control cells (Fig. 3A), this effect was
statistically signiﬁcant only for the KRT14mut cells. After adding 4-
PBA, adhesiveness was unaltered in control cells, but decreased in EBS
keratinocytes (Fig. 3A). Second, using the spinning disk assay [26], we
estimate the adhesiveness of cells to the ECM by applying different
ﬂuid shear stresses to adherent cells, and measuring the fraction of
cells that remain attached in this process. This assay is relevant for the
in vivo situation of keratinocytes, where they are exposed to high me-
chanical stresses. The fraction of adherent cells was higher in EBS
keratinocytes compared to control cells (Fig. 3B, left panel). 4-PBA treat-
ment resulted in signiﬁcantly lower numbers of adherent cells, both
NHK and EBS (Fig. 3B, right panel). Thus, all three assays show that 4-
PBA impaired both cell-cell and cell-ECM adhesion in control, and
even more so in KRT5mut and KRT14mut cells. Impairment of cell-cell
adhesion due to 4-PBA treatment was dose-dependent. After treatment
with 1 mM 4-PBA the cells detached at a ~twofold higher rate in the
dispase-dissociation assay (Fig. 2A), whereas after treatment with
10 mM 4-PBA they detached at a ~tenfold higher rate (Supplemental
Fig. 3A, left panel). Similar effects were observed with the keratinocyte
adhesion to the underlying uncoated tissue culture plastic (Supplemen-
tal Fig. 3A, right panel).
We then analyzed the effect of 4-PBA on cell migration with an
in vitro wound healing assay. EBS keratinocytes migrated faster than
control cells; this was especially pronounced in the KRT5mut cells,
where thewound areawas completely closedwithin 9 h (Supplemental
Fig. 4A and B). Treatmentwith 4-PBA considerably inhibited cellularmi-
gration. In the control keratinocytes around 70% of the wound area was
closed after 9 h, whereas after 1 mM 4-PBA treatment only 60% of the
wound area was closed. The KRT5mut cells closed the wound area
within 9 h, whereas around 10% of the area remained open when the
cells were treated with 1mM 4-PBA. For the KRT14mut cells, the effects
were even more pronounced. Untreated KRT14mut cells almost closed
the wound area within 9 h, whereas with 1 mM 4-PBA treatment
N45% of the wound area was still open (Supplemental Fig. 4C). The im-
pact of 4-PBA treatment on cell migrationwas dose-dependent; cell mi-
gration nearly stopped at a dose of 10mM4-PBA (Supplemental Fig. 3).
To understand the deleterious effects of 4-PBA on EBS cellmigration,we
also stained for the focal adhesion-associatedmolecules integrin β1 and
for F-actin, as visualized by phalloidin. Integrinβ1was greatly enhanced
after 4-PBA treatment especially in control and KRT5mut cells, probably
as a compensatorymechanism to long-term reduced adhesion (Fig. 3C).
4-PBA treatment resulted in altered staining of the epidermal F-actin cy-
toskeleton in control and EBS keratinocytes, whereas the total amount
of F-actin was unchanged, as shown by immunoblotting, suggesting al-
tered distribution of the actin ﬁlaments in the cells (Fig. 3D). Although
values did not reach statistical signiﬁcance, we also found increased
abundance of laminin-332 in cells after 4-PBA treatment (Fig. 3E). This
correlated with the reduced motility of the treated keratinocytes [27]
(Supplemental Fig. 3). Together, our data highlight that 4-PBA treat-
ment impairs adhesion and migration of EBS keratinocytes, despite up-
regulation and re-organization of several proteins involved in adhesion
andmigration. These effects are dose-dependent; higher 4-PBA concen-
trations inhibit keratinocyte migration (Supplemental Fig. 3B) and
cause detachment of the cells.
2.4. 4-PBA reduces apoptosis and inﬂammatory signaling in EBS cells
To assess the effects of long-term 4-PBA treatment on cell ﬁtness, we
treated primary control human keratinocytes (NHK) with 1 mM and5 mM 4-PBA every 2 days for 1 week or left the cells untreated.
Keratinocytes growthwas evaluatedwith the colony-forming efﬁciency
assay, which showed that 4-PBA treatment reduced cell growth, as
quantiﬁed by the colony size (Fig. 4A). In addition, the colony size de-
creased with increasing 4-PBA dosage, indicating that 4-PBA treatment
either reduces keratinocytes proliferation or enhances cell death, e.g. by
apoptosis. Enhanced apoptosis has been described as a possible patho-
genetic mechanism in genetic disorders with aggregate formation
[28]. Thus, we visualized apoptotic cells by ﬂow cytometry using the
Annexin V binding assay. We found increased numbers of apoptotic
cells (statistically signiﬁcant for EBS cells in late apoptosis) in EBS
keratinocyte cell lines compared to the control keratinocytes, irrespec-
tive of the underlying keratin mutations. EBS cells have been reported
to be more susceptible to apoptosis [29,30], although in at least one re-
port, KRT14mutant cells showed higher resistance to apoptosis follow-
ing mechanical stress- that was reversed by inhibiting ERK [10]. 4-PBA
treatment had divergent effects in NHK and EBS cells. In NHK cells, it in-
duced apoptosis. In EBS cells, apoptosis decreased after 4-PBA, possibly
as a result of the reduced aggregates (Fig. 4B). Apoptosis has also been
linked to inﬂammation and to increased IL1β levels [31]. IL1β is a potent
player in cutaneous inﬂammation and has been proposed to be highly
expressed in EBS skin [32]. Thus, we evaluated the expression of IL1β
in untreated and 4-PBA-treated NHK and EBS cells. We found signiﬁ-
cantly enhanced IL1β levels in EBS cells, whereas 4-PBA treatment re-
duced IL1β levels (Fig. 4C), thus linking enhanced IL1β to the presence
of pathogenic keratin IF aggregates in EBS pathogenesis. Intriguingly,
treatment of NHK cells with 1 mM 4-PBA resulted in enhanced IL1β
levels (Fig. 4C).2.5. Global proteomics analysis reveals reduced expression of desmosomal
and ECM molecules
To gain a better understanding on how 4-PBA treatment inﬂuenced
molecular processes in EBS, we performed unbiased mass
spectrometry-based proteomics of control and EBS keratinocyte cell
lines. Two different cell lines for each group, control (NHK), KRT5mut
and KRT14mut cells, weremetabolically labeled using stable isotope la-
beling by amino acids in cell culture (SILAC) [33]. Differentially labeled
cells, untreated and treated with 4-PBA respectively, were mixed,
lysed in SDS buffer, proteins were separated by SDS–PAGE and digested
in-gel using trypsin. The resulting peptide mixtures were analyzed by
quantitative liquid chromatography-mass spectrometry. In total 3′292
proteins were identiﬁed, of which 2′779 could be quantiﬁed in at least
one sample. Of these, 1′097 were present in all samples and employed
for further analysis using hierarchical clustering (Supplemental
Table 1). Changes in the proteomic composition after 4-PBA treatment
are presented as a heat map (Fig. 5A) and show that KRT5mut and
KRT14mut cells clustered together, highlighting global, EBS-speciﬁc dif-
ferences after 1 mM 4-PBA treatment compared to NHK cells (Fig. 5A).
Two large clusters were identiﬁed comprising differentially, co-
regulated proteins in EBS, clusters 7 and 12 (Fig. 5A). GO term analysis
of respective proteins revealed enrichment of the GO terms “cellular
or carboxylic acid metabolic process” and “catabolic process” in cluster
12,whereas in cluster 7 terms related to “cell adhesion”, “actin cytoskel-
eton and extracellular matrix organization” and “developmental pro-
cess” were enriched (Fig. 5A). This indicates that 4-PBA impacts cell
adhesion and organization of both the actin cytoskeleton and the ECM
more strongly in EBS cells than NHK cells. In addition, to uncover cellu-
lar pathways responsive to 4-PBA treatment that are common in NHK
and EBS cells, we compared treated versus non-treated cells and ana-
lyzed signiﬁcantly regulated proteins on potential interactions.We con-
structed two networks of signiﬁcantly regulated proteins after 4-PBA
treatment in NHK and EBS cells (Fig. 5B). These included mostly pro-
teins of the cytoskeleton and the extracellular matrix. Also, proteins in-
volved in ubiquitination were detected.
Fig. 2. 1mM4-PBA results in loss of cell-cell adhesion through diminished cell-cell contacts. A In the dispase-based dissociation assay the 1mM 4-PBA-treated cells detached signiﬁcantly
easier resulting inmore fragments and thus reﬂecting disturbed cell-cell contacts [for NHK+, KRT14mut+ and KRT5mut+: ***P b .0001, student's t-test]. B Immunoﬂuorescence staining
with anti-desmoplakin (red) antibodies to visualize desmosomes, and anti-plakoglobin (green) antibodies to demonstrate adherence junctions, in NHK was performed after calcium
switch. Both were reduced and their localization at the cell-cell junctions was lost after treatment with 1 mM 4-PBA. Scale bar: 50 μm. C Immunoblotting for desmoplakin, E-cadherin
and plakoglobin revealed reduced abundance after 1 mM 4-PBA treatment, whereas β-catenin was found enhanced. Bar graphs on the right show expression of these proteins
normalized to tubulin as percentage of expression in untreated cells [desmoplakin: P= .2383 for KRT14mut and *P = .0343 for KRT5mut; E-cadherin: P= .0787 for KRT14mut and
**P= .0023 for KRT5mut; β-catenin: P= .0675 for KRT14mut and P = .7116 for KRT5mut; plakoglobin: *P= .110 for KRT14mut and *P = .0220 for KRT5mut, all done with paired
student's t-test].
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tional cytoskeletal proteins, among them desmoplakin and other mem-
bers of the plakin family, was reduced after 4-PBA treatment (Fig. 5B). In
addition, several ECMproteinswere reduced both in NHK and EBS cells,
e.g. thrombospondin 1,ﬁbronectin and collagenVII, as conﬁrmed by im-
munoblotting (Fig. 5C). After 4-PBA treatment of NHK, the expression of
all proteins was reduced but reached statistical signiﬁcance only for col-
lagen VII. Physiologically, these proteins are associated with wound
healing response, explaining the adverse effects of 4-PBA on cell-
matrix adhesion and defective wound closure.
2.6. Proteomics reveals co-induction of the NF-kB and Wnt signaling
pathways
Furthermore, proteomics revealed additional signiﬁcantly
deregulated proteins that are linked to enhanced cell proliferation and
activation of the NF-κB pathway. Selected molecules were further ana-
lyzed for their expression on mRNA level with qPCR. PPFIA4, a member
of the liprin family associatedwith epithelial contact formation,was en-
hanced in the proteome and the quantitative PCR (qPCR) after 4-PBA,
probably as a compensatory approach to cellular dissociation [34] (Sup-
plemental Fig. 5). The PPFIA4 genepromoter is activated after binding of
the hypoxia-inducible factor 1α, a molecule linked to NF-κB signaling.
Similarly, the HECT-domain ubiquitin ligase HERC3 [35], amphiregulin[36] and the low-density lipoprotein receptor-related protein 1 (LRP1)
[37] were signiﬁcantly (P b .05) upregulated after 1 mM 4-PBA treat-
ment at the protein level. Measurements at the mRNA level conﬁrm
this observation, although not all data points reached statistical
signiﬁcance.
The 4-PBA-induced abundance of molecules involved in NF-κB acti-
vation in keratinocytes, prompted a more detailed investigation of this
pathway. E-cadherin was reduced by 4-PBA, but we also noted some
round vesicles around the nucleus (Fig. 6A), an indication of perinuclear
accumulation of E-cadherin, which is known to activate both the NF-κB
and Wnt/ β-signaling pathways [38]. Both pathways are implicated in
cell proliferation, which increased dose-dependently in 4-PBA-treated
cells (Fig. 6B and Supplemental Fig. 3C). The NF-κB pathway is a central
regulator of inﬂammation and modulates a spectrum of biological pro-
cesses; it can be activated by canonical and non-canonical pathways
[39]. In the canonical pathway, (RelA/p65)/p50 heterodimers are main-
tained in the cytoplasm in an inactive state by a family of inhibitors of
NF-κB (IKBα). These IKBα inhibitors were expressed at lower levels in
EBS cells compared to NHK before treatment, although there was
some variation between the KRT14mut cell lines. After 4-PBA treatment,
the expression of IKBα inhibitors decreased even more (Fig. 6C). Upon
activation of the pathway, IKBα becomes phosphorylated leading to
its degradation and the subsequent release of the RelA/p50 heterodi-
mer. These newly liberated RelA/p50 heterodimers can translocate to
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tory mediators, such as COX2, TNFα, and IL-6 [39]. Indeed, after 4-PBA
treatment in both NHK and EBS cell lines IKBα and ERK were more
phosphorylated (Fig. 6C), which is also in line with the observed in-
creased proliferation (Fig. 6B and Supplemental Fig. 3C).
Intriguingly, TNFαwas upregulated after 4-PBA treatment (Supple-
mental Fig. 6), probably as a result of negative regulation of IL1β [40]
(Fig. 6C). The NF-κB pathway either positively or negatively regulates
Wnt / β-catenin signaling, which exerts both anti-inﬂammatory and
proinﬂammatory functions [41]. β-Catenin is a central mediator of the
Wnt signaling cascade and functions as an adhesion molecule, linking
E-cadherin to the actin cytoskeleton. In the absence ofWnt stimulation,
β-catenin in the cytoplasm is constitutively targeted for degradation.
Upon Wnt activation, the degradation complex is inactivated, resulting
in cytoplasmic accumulation of β-catenin. After translocation into the
nucleus, β-catenin associates with T cell factor/lymphoid enhancer fac-
tor (TCF/LEF1) transcription factor and promotes the transcription of its
target genes. Here, we observed enhanced LEF1 staining after 4-PBA
treatment in the EBS cells, whereas β-catenin was the only adhesion
molecule that was found upregulated after 4-PBA in immunoblot
(Fig. 2C), having lost its localization at the cell-cell contacts (Fig. 6D
and Supplemental Fig. 7A). These results indicate that theWnt signaling
pathway is also activated upon 4-PBA treatment.
2.7. 3D skin equivalents conﬁrm results on cellular level
To test whether the beneﬁcial or adverse effects of 4-PBA on EBS-
cells are critical in a more physiological, tissue-like environment and
since no viable EBS animal model is available, we used three-
dimensional (3D) skin equivalents. The skin equivalents were devel-
oped by use of control keratinocytes vs EBS cells for the epidermal
part, and normal human ﬁbroblasts for the dermal part. The skin equiv-
alents grew in their chambers for 4 weeks, inwhich theywere treated 3
x weekly with 1 mM 4-PBA. We observed a few areas of dermo-
epidermal detachment in the EBS skin equivalents, but not in the
controls. In the 4-PBA treated equivalents, however, several intra- and
subepidermal splits were found (Fig. 7A, black arrows; 7B and C, yellow
arrows). Laminin-332 and integrin β4 showed abnormal staining pat-
terns after 4-PBA treatment in the NHK and EBS skin equivalents
(Fig. 7 B and C). Laminin-332 deposition was irregular and patchy in
the NHK, whereas it also stained the suprabasal keratinocytes in the
EBS cells. Similarly, integrin β4 had a more pronounced, irregular,
suprabasal patchy expression in the treated skin equivalents. Thus, 4-
PBA treatment perturbs laminin-332 organization, which in turn
seems to abrogate the polarized expression of integrin α6β4 in basal
keratinocytes. β-catenin showed a more cytoplasmic localization in
the EBS skin equivalents, having lost its localization at the cell-cell con-
tacts, which was evenmore pronounced in the treated EBS, but also the
treated NHK skin equivalents (Supplemental Fig. 7A). Finally, nuclear
localization of the p65 subunit of NF-κB was signiﬁcantly increased in
the epidermal part of the treated NHK and EBS skin equivalents, indica-
tive of activation of the transcription factor (Supplemental Fig. 7B). This
3Dmodel, as a straight-forward approach to imitate the situation in the
human skin, conﬁrmed our previous results on cellular level. Together,Fig. 3.Cell-ECM interactions are disturbedwith enhanced focal adhesions after 1mM4-PBA trea
collagen I or left on untreated plates. We refer to the adhesion of the untreated cells on collag
whereas signiﬁcant effects were found in 4-PBA-treated KRT14mut and less in KRT5mut
Reduction of the fraction of adherent cells in NHK and EBS cells in the spinning disk assay aft
P = .6818]. The effect of 4-PBA on adhesiveness is signiﬁcant, with NHK and EBS cells take
associated molecule integrin β1 (green) was stained and found greatly enhanced after 1 mM
treatment resulted in altered staining of the epidermal F-actin cytoskeleton in control and
immunoblotting, suggesting altered distribution of the actin ﬁlaments in the cells [for KRT14m
stainings were done in triplicates with at least 2 different cell lines for each group, before and a
blotting for laminin-332 revealed increased amounts in cell lysates after 1mM4-PBA treatment
age of expression in untreated cells. Values represent mean ± S.E.M., paired t-test was used; four data highlight that 4-PBA has a dose-dependent negative impact
on cell adhesion and migration in the skin.
3. Discussion
EBS is an inherited skin fragility disorder with so far only symptom-
atic treatment options so far. In the last years therapies aiming at
symptom-relief have gained attention in the ﬁeld of genetic disorders.
Although some successful curative therapy approaches have been de-
scribed for other types of EB [42], their clinical implementation still
lies in distant future. Symptom-relief therapies are being developed
on the basis of detailed knowledge of molecular and cellular pathoge-
netic mechanisms; they target key molecules involved in major symp-
toms. In case of EBS, the KRT5 and KRT14mutations induce IF network
aggregateswithin the keratinocytes and cause reduced resilience tome-
chanical stress. The presence of the aggregates is mutation-dependent,
but also dependent on the thermal or chemical stress applied to
the cells. 4-PBA is an approved orphan drug, which has been shown
to inhibit protein aggregation and thus ameliorate disorders
associatedwith this phenomenon [16]. Thus, targeting the keratin IF ag-
gregates with 4-PBA seemed a promising approach, and we therefore
analyzed its effect on our KRT5mut and KRT14mut cell lines in different
dosages.
We identiﬁed contrasting effects of 4-PBA treatment on EBS cells. Al-
though 4-PBA reduced IF aggregates at a dose of 1mM, it negatively im-
pacted keratinocyte adhesion. The effect of thermal and chemical stress
on aggregate formation was more pronounced in KRT14mut than
KRT5mut cells, as was also the disruptive effect of 4-PBA on cell-cell
and cell-ECM adhesion. The cell-cell contacts were disturbed in 4-PBA
treated cells regarding localization and abundance of the desmosomal
and adherence junction proteins. The cells employed compensatory
mechanisms to overcome the diminished adhesion, e.g. by upregulating
the focal adhesion integrin β1 and laminin-332, a pivotal adhesion li-
gand for keratinocytes. This was associated with increased proliferation
and reduced migration of the cells.
Taken together, there were some effects of 4-PBA that both EBS cells
had in common: reduction of aggregates, reduction of cell-cell adhesion
(as shown by the dispase-dissociation assay and the reduced cell-cell
contacts in stainings and immunoblots) and reduction in inﬂammatory
markers. 4-PBA treatment had a greater negative impact on
keratinocyte migration and cell-matrix adhesion of the KRT14mut
than the KRT5mut cells. On the other side, increase in proliferation
and its associated molecules in skin, e.g. KRT6 was observed signiﬁ-
cantly more in KRT5mut cells. These differences can probably be attrib-
uted to 2 major points: a) the KRT14mut cells had more aggregates
already at resting state than the KRT5mut, and b) although these pro-
teins form very stable subunits, their functions might be disparate e.g.
regarding their role in keratinocyte survival and proliferation. One
could only speculate that the aggregate production in the EBS cells is
part of a compensatory mechanism of the cells, which results in en-
hanced cell-matrix adhesion. The aggregate reduction impacts more
the KRT14mut cells, which hadmore aggregates to beginwith, probably
explaining the greater effects in adhesion. It might be that different
compounds would be required to stabilize the cytoskeleton intment inNHK and EBS cells. A For the keratinocyte adhesion assay, the cellswere coated on
en I as 100% adhesion. After 4-PBA treatment, the adhesion of NHK appeared unchanged,
cells [for KRT14mut + *P = .0411 and for KRT5mut + P = .3267, student's t-test]. B
er treatment with 1 mM 4-PBA [NHK+ P= .4296; KRT14mut + P= .0652; KRT5mut +
n together (All cells vs all cells+: *P = .0001, student's t-test). C The focal adhesion-
4-PBA treatment especially in control and KRT5-mutated cells. Scale: 200 μm. D 4-PBA
EBS keratinocytes, whereas the total amount of F-actin was unchanged, as shown by
ut + P= .9092 and for KRT5mut + P= .1796, student's t-test]. Scale bar: 50 μm. The IF
fter 4-PBA treatment. Shown are representative results from one experiment. E Immuno-
. Bar graphs on the right show expression of laminin-332 normalized to tubulin as percent-
or NHK P= .6097, for KRT14mut P= .4084 and for KRT5mut P= .6291.
Fig. 4. Effects of 1 mM 4-PBA on cell apoptosis and IL1β expression. A. Colony-forming efﬁciency assay of 4 different primary NHKs, treated with different dosages of 4-PBA for 1 week is
shown (untreated, 1 mM and 5mM4-PBA every 2 days). The 4-PBA-treated cells had a clearly reduced growth potential compared to untreated keratinocytes, as visualized by the colony
size. Colony size decreasedwith increasing 4-PBAdosage. B Cellswere stainedwith annexinV / DAPI and then visualizedwithﬂow cytometry to detect apoptotic cells. The experimentwas
done in triplicates with 2 different cell lines for each group. Bar graphs of all experiments show clearly increased numbers of apoptotic cells (especially late apoptotic) in the EBS
keratinocyte cell lines compared to NHK; irrespective of the underlying keratin mutations (differences in NHK versus NHK+ [+ standing for cells treated with 1 mM 4-PBA]: necrotic
cells P = .1061, late apoptotic cells P= .0955, early apoptotic cells P= .1946 and viable cells P= .0817; differences in KRT14mut versus KRT14mut+: necrotic cells P= .7449, late
apoptotic cells *P= .0249, early apoptotic cells P = .9868 and viable cells P= .0979; differences in KRT5mut versus KRT5mut+: necrotic cells P= .5548, late apoptotic cells **P=
.0097, early apoptotic cells P= .1967 and viable cells *P= .0211). Thus, 4-PBA treatment had different effects in NHK and EBS cells. In NHK it induced apoptosis, whereas in the EBS
cells it reversed apoptosis. Values represent mean ± S.E.M., unpaired t-test was used. C Total IL1β abundance was evaluated by dot blots in untreated NHK and EBS and 4-PBA treated
cells. For the experiment two NHK, two KRT14mut and two KRT5mut cells were used, before and after treatment with 1 mM 4-PBA were used. The experiment was performed in tripli-
cates. The data of the KRT14mut and KRT5mut cells were pulled together for the statistical analysis, since they were similar. Shown above is a representative picture of one NHK and one
KRT5mut cell line, before and after 4-PBA treatment. IL1β expression was higher in EBS cells compared to NHK prior to 1 mM 4-PBA treatment, whereas after treatment, IL1β expression
was lower in EBS cells compared to NHK cells. Values represent mean ± S.E.M., unpaired t-test was used; for NHK versus EBS **P= .0096, for EBS+ 1 mM 4-PBA *P= .0257.
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that the aggregate reduction is by itself not sufﬁcient to stabilize the
cytoskeleton.
Using the current conditions, 4-PBA represents not a viable treat-
ment option for EBS, however, lower concentrations of 4-PBA in combi-
nation with anti-inﬂammatory drugs may act more selectively againstaggregated keratins. In addition, other drugs targeting the aggregate
formation are deﬁnitely worth being investigated for their effects at a
cellular and tissue level. Keratin aggregates can induce inﬂammation
[43,44]. Our results indicate that 4-PBA treatment reduced not only cel-
lular aggregates, but also apoptosis of EBS cells and IL1β secretion. In a
similarmanner, proteinmisfolding induces cellular stress and promotes
Fig. 5. Proteomics reveals effects of 4-PBA treatment on extracellular matrix and cytoskeleton proteins. A Heatmap of hierarchically clustered protein abundance ratios comparing 4-PBA-
treated cells. SILAC ratioswere log2-transformed andnormalized (z-score). Samples and protein ratioswere clusteredhierarchically. On the left, the different clusters are shown. Clusters 7
and 12 are differentially regulated inNHK versus EBS cells. On the right, the GO terms enriched in each Cluster are shown. B Proteins that were signiﬁcantly affected by 4-PBA treatment in
minimally one of the samples (Signiﬁcance A, p b .05, BH corrected) carrying GO terms related to extracellular matrix and cytoskeleton were short-listed and analyzed on potential
interactions using default settings in STRING DB. C Western blot analysis to test the identiﬁed targets shows reduced expression of thrombospondin 1 (THBS1), ﬁbronectin 1 (FN1)
and collagen VII (Col VII). Bar graphs on the right show the quantiﬁcation of 3 subsequent experiments done with 2 different EBS cell lines. Shown are the mean ± S.E.M. of the
normalized protein abundance. Paired t-test was used to calculate signiﬁcance [THBS1: for NHK P= .1497, for KRT14mut P= .6293 and for KRT5mut P = .0947; FN1: for NHK P=
.1180, for KRT14mut P= .5414 and for KRT5mut P= .2840; ColVII: for NHK *P = .0211, for KRT14mut P= .1498 and for KRT5mut P= .2911].
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terminant in EBS deserves a closer look.
We employed unbiased global proteomics to connect the observed
changes on a cellular level tomolecular events. Analysis of EBS and con-
trol keratinocytes after 1 mM 4-PBA treatment uncovered reduced
abundance of ECM proteins and proteins of the cytoskeleton, however,
this failed to enhance cell-cell and cell-matrix adhesion which are cru-
cial in skin fragility disorders. The reduction of E-cadherin is possibly a
central event, since loss of cadherin-mediated adhesion is associated
with increased Wnt signaling through β-catenin and co-induction of
the NF-κB pathway. Actin cytoskeleton disruption has been linked to
NF-κB activation [46]. In addition, loss of another adherence junction
protein, p120-catenin, has been shown to be associated with activated
NF-κB, as an intrinsic response to loss of p120 rather than extrinsic con-
sequence of inﬂammation [47]. In our cells, this activation was com-
bined with increased cell proliferation and enhanced TNF-α
expression, contrasting the observed IL1β reduction and reﬂecting
how complex the induction of such central pathways as NF-κB, is. We
postulate that the reduced IL1β levels are directly linked to the loss of
the aggregates in the cell, whereas increased TNF-α reﬂects a secondary
event to NF-κB and Wnt signaling activation.
Taken together, we show that lowdose 4-PBAhas some favorable ef-
fects on EBS cells. What our data make clear though is that higher doses
of 4-PBA are toxic for keratinocytes, thus the drug should be avoided in
skin fragility disorders. Othermolecular chaperones targeting aggregate
formation and ER stress could represent possible therapeutic tools,
however their effects on cellular adhesion and migration must ﬁrst be
carefully investigated.4. Material and methods
4.1. Clinical samples and cell culture
EBS diagnosiswas based on clinical assessment, morphological anal-
ysis of skin biopsies and ﬁnally mutation analysis. After informed con-
sent, skin biopsies and ethylenediaminetetraacetic acid (EDTA) blood
was obtained from the patients for diagnostic purposes. The project
was approved by the ethics committee of the University of Freiburg
and was conducted according to the Declaration of Helsinki principles.
Skin samples from EBS patients and from healthy individuals who
underwent surgery were used after informed written consent for
immunostainings and isolation of keratinocytes. Primary keratinocytes
from patients' and control skin were cultured in serum-free
keratinocytemedium supplemented with 25 μg/ml bovine pituitary ex-
tract and 0.2 ng/ml recombinant epidermal growth factor (Invitrogen,
Darmstadt, Germany) using standard methods (Kiritsi et al., 2011).
The immortalization was performed after co-transfection of the cells
with the HPV18 E6 and E7 genes (pLenti-III-HPV-16 E6/E7 lentivector,
ABM, Richmond, Canada), as described before [48].4.2. Cell treatments
Cell treatments were performed in six-well plates, with 0.3 to
0.4× 106 cells seeded the day before treatment and incubated overnight
at 37 °C and 5% CO2. 4-PBA (Sigma-Aldrich), a chemical chaperone, was
used at a concentration of 1 and 10 mM for 24 or 48 h. For inhibition of
Fig. 6. 4-PBA treatment co-induces theNF-κB and theWnt signaling pathways in EBS cells. A Immunoﬂuorescence stainingwith E-cadherin (green)was reduced after 4-PBA treatment; in
addition, some round vesicles around the nucleus were present in all cell lines as an indication of perinuclear accumulation of E-cadherin. Scale bar: 50 μm. B Cell proliferation was
enhanced in all cell lines after 1 mM 4-PBA treatment. C Immunoblotting for IKBα showed reduced levels in EBS cells compared to NHK before treatment, although there was some
variation between the KRT14mut cell lines. After 4-PBA treatment, IKBα decreased even more [for NHK P = .4113, for KRT14mut *P = .0275 and for KRT5mut **P = .0094].
Phosphorylated IKBα (pIKBα) was enhanced after 4-PBA treatment in the KRT5mut cells [for NHK P= .8099, for KRT14mut P= .1041 and for KRT5mut *P = .0257]. Phosphorylated
ERK (pERK) was signiﬁcantly enhanced in the EBS cell lines [for NHK P = .2128, for KRT14mut *P = .0133 and for KRT5mut *P = .0409]. Bar graphs on the right show the
quantiﬁcation of 3 subsequent experiments. Shown are the mean ± S.E.M. of the normalized protein abundance. Paired t-test was used to calculate signiﬁcance. D Staining for the
lymphoid enhancer factor (LEF1) (green, left panel) is enhanced after 4-PBA treatment in all cell lines. Immunoﬂuorescence staining for β-catenin (red, right panel) demonstrating
adherence junctions appears enhanced and more diffuse after 4-PBA treatment in the EBS cells (arrows point to the cell-cell contacts, which seem diminished after 4-PBA). Scale bar:
50 μm.
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(Calbiochem, Darmstadt, Germany) for 6 h.
4.3. Immunoblot analysis
Immunoblot analysis was performed as described before [13,49]
using primary antibodies to desmoplakin, E-cadherin, β-catenin,plakoglobin, keratin 14, keratin 17, keratin 6, keratin 16, IKBα and
phosphorylated- IKBα, ERK and phosphorylated-ERK, and tubulin to
control loading (see Supplemental Table 2). For the analysis of IL-1β
and Tnf-α, dot blots were performed. Blots were developed using ECL
substrate (Thermo Scientiﬁc, Rockford, IL) and the Fusion SL system
(Peqlab, Erlangen, Germany). The signals obtained from Western blot
analyses were densitometrically quantiﬁed with ImageJ's gel analysis
Fig. 7. Skin equivalents with NHK and EBS cells show several intra- and subepidermal splits after 1 mM 4-PBA treatment, as well as perturbed staining patterns of laminin-332 and of
integrin β4. A Skin equivalents with control vs EBS keratinocytes for the epidermal part and control normal human ﬁbroblasts for the dermal part were employed to assess the effect
of 4-PBA in a 3D model. Only a few areas of dermo-epidermal detachment are present in the EBS skin equivalents compared to the control skin equivalents, as shown with
haematoxylin/ eosin staining. In the 4-PBA treated skin, however, several intra- and subepidermal splits (black arrows) were found, corroborating the adhesion defect. Scale: 100 μm.
B Laminin-332 deposition was irregular and patchy in the NHK, whereas it also stained the suprabasal keratinocytes in the EBS cells. In the 4-PBA treated skin, again, several intra- and
subepidermal splits (yellow arrows) were observed. Scale: 100 μm. C Integrin β4 showed also an irregular and more pronounced, patchy, suprabasal expression in the treated skin
equivalents. Thus, 4-PBA treatment perturbs laminin-332 organization, which in turn seems to abrogate strictly polarized expression of integrin α6β4 in basal keratinocytes. The
yellow arrows depict intra- and subepidermal splits, present mostly in the 4-PBA treated skin. Scale: 100 μm.
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in untreated cells after normalization to loading control.
4.4. Indirect immunoﬂuorescence staining
Cells were seeded on uncoated coverslips and allowed to grow for
two days, ﬁxed and processed as described [50]. Before ﬁxing the cells,
they were switched to media containing 1.2 mMCa2+ for 24 h. Primary
antibodies used in this study were the following: keratin 5, plectin, des-
moplakin, E-cadherin, phalloidin, integrin β1, β-catenin, plakoglobin
(see Supplemental Table 2). Nuclei were visualized with DAPI. As
secondary antibodies, Alexa anti-rabbit IgG, anti-guinea pig IgG and
anti-mouse IgG (Invitrogen) were used. Images were captured by im-
munoﬂuorescence microscopy (Zeiss Axio Imager, Zeiss, Germany).
The software ImageJ was applied for quantiﬁcation, and GraphPad
Prism for statistical analyses.
4.5. Dispase-based dissociation assay
Control and EBS cells were seeded in triplicates; 24 h after reaching
conﬂuence, the cells were treated with 1.2 mM Ca2 overnight. The cul-
tures were washed twice in Dulbecco's PBS (DPBS) and then incubated
in 1mg/ml dispase for 30min. Phase-contrast imageswere taken before
and after dispase digestion. The released monolayers were washed
twice with DPBS and transferred to 15 ml conical tubes. The tubes
were secured to a rocker and subjected to 50 inversion cycles. The frag-
ments were counted using an inverted microscope.
4.6. Spinning disk method
The spinning disk consists of a stationary plate (petri dish) and a ro-
tating glass plate driven by air pressure [26]. The applied shear stress
depends on the rotation frequency of the spinning plate, the distance
between rotational and stationary plate, and the viscosity of the cell cul-
ture medium. In these experiments we used a rotational frequency of
1500 rpm and a plate distance of 150 μm. We seeded 15.000 cells per
well and cell line in 1.5 ml medium for 24 h. Cell nuclei where stained
with Hoechst dye prior to ﬂuid shear stress application. Images of the
cells (both in brightﬁeld and ﬂuorescent mode) were taken before and
after 5 min of stress application. A series of images were recorded,
starting from the middle of the dish and then 10 ﬁeld of views radially
outwards (x-direction). We also recorded adjacent 3 ﬁelds of views
for each x-position going in the y-direction. For evaluating the fraction
of attached cells, we used the program “Clickpoints” [51] to count the
cells in a region between 2 and 4 mm distance from the dish center,
where the shear stress was between 7 and 15 dyn/cm^2 (0,7 to 1,5 Pa).
4.7. Migration, proliferation and cell adhesion assays
To investigate the migration of the keratinocytes, an in vitro wound
closure assay was performed. The keratinocytes were cultured to
conﬂuency on Ibidi μ-dishes with culture-inserts. After removal of the
inserts, the cells were rinsed with PBS and incubated further in culture
medium under 5% CO2 at 37 °C in a Nikon Biostation immunoﬂuores-
cence microscope (Nikon Instruments Inc., Melville, NY). Photographs
were captured every 60 min for 24 h and the wound areas were mea-
sured using the Image J software. For assessment of proliferation,
keratinocytes were seeded on micro plates with a local ionic electrode
interface. The cells were monitored over the course of at least 4 days.
For the cell adhesion assay tissue culture wells were coated with
10 ng/ml of collagen I (Sigma-Aldrich, Munich, Germany) or left on un-
treated plates at 4 °C overnight. After saturation with 1% BSA, equal
numbers of cells were seeded. The keratinocytes adhered for 1 h at 37
°C, then were ﬁxed with ethanol and stained with 0.5% crystal violet
for 15 min. Adherent cells were photographed and quantiﬁed by mea-
suring the optical density at 540 nm.4.8. Colony-forming assay
Around 1000 cells from primary normal human keratinocytes were
seeded on 6 cm tissue cultures dishes. They were incubated for 7 days
with 1 mM or 10 mM 4-PBA on 37 °C, 5% CO2. Media were changed
every 2 days. The cells were ﬁxed with formalin / PBS for 15 min
at room temperature. After washing with PBS, they were stained
with 0,05% crystal violet in PBS, after incubation for 1 h at room
temperature.
4.9. Organotypic skin equivalents
3D organotypic co-cultures were prepared as described before [52]
to evaluate the effects of 4-PBA treatment on cell adhesion. The co-
cultures were constructed with control human or KRT5- or KRT14-
mutated keratinocytes as epithelial cells and normal human ﬁbroblasts,
forming a skin-like bilayered structure. 4-PBAwas givenwith everyme-
dium change at a dosage of 1 mM in the cell medium.
4.10. Software for classiﬁcation of the cells
For counting and classifying cells grownon a coverslip into cellswith
or without aggregates after immunoﬂuorescence staining, custom pro-
gramswritten inMatlab and Pythonwere used. After deﬁning a starting
position on the coverslip, a 10 × 10 grid of images with an overlap of
10% in x and y direction was recorded using a 63× oil objective of an in-
verse immunoﬂuorescence microscope (Leica DMI6000 CS). At every
position, a stack of 31 z-slices (0.5 μm z-distance) was recorded,
which was joined using a maximum sharpness projection. Afterwards,
a single composite image was stitched using the stitching plugin of
ImageJ. To improve the visual appearance of the large stitched image,
the median intensity was subtracted and the contrast maximized.
Using ClickPoints software [51], cells were then manually labeled in
two categories: cells without aggregates and cells with aggregates.
The evaluation of a large region on the coverslip helps to reduce bias,
which could be introduced by manually selecting only a few ﬁelds of
view for analysis.
4.11. Annexin V binding assay
Adherent keratinocytes were dissociated from the culture plate by
trypsinization and placed as suspension in a 96-well round bottom
plate (around 100.000 cells per well), washed twice with PBS and
stained with Annexin V as indicated in the manufacturer's datasheet
(Becton-Dickinson). As positive controls, cells treated overnight with
staurosporine (1 μM) or heat treated cells were used. Necrotic cells
were stained by addition of DAPI directly before analysis of annexin-V
positive apoptotic cells by ﬂow cytometry. The experiment was per-
formed with 2 different cell lines for each category (NHK, KRT14mut,
KRT5mut) and then repeated 3 times.
4.12. Mass spectrometry (MS) analysis
For MS analysis, cells were cultured in keratinocyte growthmedium
(KGM2) (Promocell, Heidelberg, Germany)without arginine and lysine,
but with “SupplementMix” (0.004ml/ml bovine pituitary gland extract,
0.125 ng/ml recombinant human epidermal growth factor, 5 μg/ml re-
combinant human insulin, 0.33 μg/ml hydrocortisone, 0.39 μg/ml epi-
nephrine, 10 μg/ml human holo transferrin) and 0.06 mM CaCl2,
210 mg/l L-arginine and 63 mg/l L-lysine for the unlabeled condition.
Cells were “heavy” labeled for 2 weeks with 210 mg/l L-arginine-
13C6-15 N4 (Arg10) and 63 mg/l L-lysine-13C6-15 N2 (Lys8) or “me-
dium-heavy” labeled with 210 mg/l L-arginine-13C6 (Arg6) and
63 mg/l L-lysine-2H4 (Lys4)31.
Cells were harvested, mixed 1:1:1 on protein level and lysates were
taken up in SDS-PAGE loading buffer. 1 mMDTTwas used for reduction
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RT). Mixed samples were separated on gradient gels of 4–12%. Gel
lanes were cut into 10 slices each, proteins therein were digested with
trypsin and the resulting peptide mixtures were processed on STAGE
tips and analyzed by LC-MS/MS as described51.
MS measurements were performed on an LTQ Orbitrap XL mass
spectrometer, which was coupled to an Easy nanoLC. Fused silica
HPLC–column tips (20 cm length, 75 μm i.d.) were packed with
Reprosil–Pur 120 C18-AQ, 1.9 μm (Dr. Maisch). Samples were loaded
on the column. A gradient of A (0.1% formic acid in water) and B (0.1%
formic acid in 80% acetonitrile inwater)was used for peptide separation
(loading of sample with 0% B; separation ramp: from 5 to 30% B within
85 min). The ﬂow rate was set to 250 nL/min; for sample application it
was 600 nL/min. The mass spectrometer operated data–dependently
switching automatically between MS (max. of 1 × 106 ions) and MS/
MS. Each full scan was followed by a maximum of ﬁve tandem MS
scans in the linear ion trap (normalized collision energy of 35%; target
value 5000). Singly charged parent ions and ions with an unassigned
charge state were excluded for fragmentation. The MS mass range was
m/z = 370–2000. Resolution was set to 60,000. MS parameters: no
sheath and auxiliary gas ﬂow; spray voltage 2.3 kV; ion–transfer tube
temperature 125 °C.
MS ﬁles were processed by MaxQuant (version 1.4.1.2), which per-
forms peak detection, generation of peak lists, and database searches
using a full-length UniProt human forward-reverse database extended
with common contaminants such as enzymes used for in–gel diges-
tion52. Carbamidomethylcysteine was set as ﬁxed modiﬁcation and
protein amino–terminal acetylation and oxidation of methionine were
set as variable modiﬁcations. The quantitation mode was set to triple
SILAC. Missed cleavages was set to three, enzyme speciﬁcity was tryp-
sin/P, mass tolerance was 20 ppm for ﬁrst search, and MS/MS tolerance
was 0.5 Da. After recalibration, averagemass precision of identiﬁed pep-
tides was b1 ppm. Peptide identiﬁcation and relative quantiﬁcation of
proteins was performed using following criteria: 2 min ‘match-be-
tween-run’, 0.01 peptide and protein FDRs, minimum peptide length
of 6, minimum number of peptides for identiﬁcation and quantitation
of proteins of 1 unique, minimum ratio count 2. Identiﬁed proteins
were re-quantiﬁed.
4.13. Statistical analysis
The GraphPad Prism 5.03 software was used for statistical analysis,
and data were analyzed using paired or unpaired Student's t-test with
Welch correction, where appropriate. The statistical analysis of the dy-
namic disassembly of the keratin IF networks, was based on the assess-
ment of 150 cells of each keratinocyte cell line, which were manually
photographed from different optical ﬁelds and afterwards classiﬁed
into cells with or cells without aggregates.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.04.062.
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